Ideaya promotes GC Stone to CFO—but he’ll still be the top lawyer
Bay Area-based IDEAYA Biosciences, Inc., which focuses on custom cancer therapy, promoted Paul Stone to the position of chief financial officer.
Stone previously was senior VP, general counsel and head of operations for the company. As CFO, the company says, he will lead the finance, investor relations, and public relations functions, and will continue as the principal financial and accounting opfficer. Paul will also continue to oversee the legal function as general counsel. Got all that?
Prior to joining IDEAYA, Paul was with 5AM Ventures in various positions, including partner, GC and COO, and held early management and operating roles in companies launched at 5AM Ventures, including IDEAYA Biosciences (NASDAQ: IDYA), Homology Medicines, Cidara Therapeutics, and Entrada Therapeutics. Paul earlier was an executive at Ethos Pharmaceuticals, Ilypsa (acquired by Amgen), and Symyx Technologies.
“Paul brings a unique combination of financial, investment, business development, and legal experience into the role of Chief Financial Officer at IDEAYA Biosciences. He is a proven biotechnology executive, and has been instrumental in executing on several key milestones for IDEAYA, including the license of Phase 1/2 PKC inhibitor IDE196 from Novartis, and our initial public offering on NASDAQ,” said Yujiro S. Hata, IDEAYA CEO and president, in a statement.